Clinical experiences with Infliximab and Adalimumab in a single centre cohort of patients with inflammatory bowel disease

Objectives: In recent years, biological therapies targeting TNF alfa have significantly improved the management of IBD refractory to conventional therapies. Our aim was to summarise our experiences of biological agents in inflammatory bowel disease (IBD). Patients and methods: Data of 86 patients with IBD were analysed [Crohn disease (CD)/ulcerative colitis (UC)]: 60/26, male/female: 52/34, age at diagnosis: 30 years, duration: 8.6 years]. Both inpatient and outpatient records were collected and comprehensively reviewed. Results: Infliximab therapy was given in 24 CD patients and 26 UC patients. Thirty-six CD pa…